JCI - Anticancer drug targets: growth factors and growth factor signaling

Anticancer drug targets: growth factors and growth factor signaling

Jackson B. Gibbs

Published in Volume 105, Issue 1

J Clin Invest. 2000; 105(1):9 doi:10.1172/JCI9084

Full text | PDF

Citation information

Citation in:
Citations:

2011
1

2010
2

2009
3

2008
4

2007
2

2005
3

2004
2

2003
4

2002
3

Total
10

Title and authors	Publication	Year	.
Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies R. Lord, A. Suddle, P. J. Ross	Int J Clin Practice	2011	.
Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells Zhimin Tong, Subhankar Chakraborty, Bokyung Sung, Pooja Koolwal, Sukhwinder Kaur, Bharat B. Aggarwal, Sendurai A. Mani, Robert S. Bresalier, Surinder K. Batra, Sushovan Guha	Cancer	2010	.
Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation Peng-Chieh Chen, Hiroko Wakimoto, David Conner, Toshiyuki Araki, Tao Yuan, Amy Roberts, Christine E. Seidman, Roderick Bronson, Benjamin G. Neel, Jonathan G. Seidman, Raju Kucherlapati	Journal Clinical Investigation	2010	.
Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells Dae-Hee Lee, Miroslaw-Jerzy Szczepanski, Yong J. Lee	J Cell Biochem	2009	.
Structure-activity relationships between the Aconitum C20-diterpenoid alkaloid derivatives and the growth suppressive activities of Non-Hodgkin’s lymphoma Raji cells and human hematopoietic stem/progenitor cells Masaharu Hazawa, Kenji Takahashi, Koji Wada, Takao Mori, Norio Kawahara, Ikuo Kashiwakura	Invest New Drugs	2009	.
Farnesyl protein transferase inhibitory components of Polygonum multiflorum Byoung-Mog Kwon, Sung-Hoon Kim, Nam-In Baek, Sa Im Lee, Eun Jeong Kim, Jae Heon Yang, Byeong Suk Chae, Jae Hyeok Lee, Hee Wook Park, Jeong-Suk Park, Dae Keun Kim	Arch Pharm Res	2009	.
EGFR Inhibitor Enhances Cisplatin Sensitivity of Oral Squamous Cell Carcinoma Cell Lines Yukihiro Hiraishi, Takeshi Wada, Ken Nakatani, Itaru Tojyo, Takashi Matsumoto, Norifumi Kiga, Kenji Negoro, Shigeyuki Fujita	Pathol Oncol Res	2008	.
Kuo-Hsiung Lee, Hideji Itokawa, Toshiyuki Akiyama, Susan L. Morris-Natschke	Wiley Encyclopedia of Chemical Biology	2008	.
Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer G. Gravis, F. Bladou, N. Salem, A. Goncalves, B. Esterni, J. Walz, S. Bagattini, M. Marcy, S. Brunelle, P. Viens	Ann Oncol	2008	.
Molecularly targeted therapies in adult soft tissue sarcomas: present approach and future directions Olivia Aranha, Mark Agulnik	eott	2008	.
Farnesyl protein transferase and tumor cell growth inhibitory activities of lipiferolide isolated fromLiriodendron tulipifera Mi Kyeong Moon, Hyun Mi Oh, Byoung-Mog Kwon, Nam-ln Baek, Sung-Hoon Kim, Ju Sin Kim, Dae Keun Kim	Arch Pharm Res	2007	.
Potential Pharmacological Interventions in Polycystic Kidney Disease Amirali Masoumi, Berenice Reed-Gitomer, Catherine Kelleher, Robert W Schrier	Drug	2007	.
Inhibitors of Epidermoid Growth Factor Receptor Suppress Cell Growth and Enhance Chemosensitivity of Nasopharyngeal Cancer Cells in vitro Chih-Hung Hsu, Ming Gao, Chi-Long Chen, Pei-Yen Yeh, Ann-Lii Cheng	Oncology	2005	.
Cripto as a target for cancer immunotherapy Xiu Feng Hu, Pei Xiang Xing	eott	2005	.
The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-κB activation induced via interaction between Akt and IκB kinase-β in breast cancer cells Franck Vandermoere, Ikram El Yazidi-Belkoura, Eric Adriaenssens, Jérôme Lemoine, Hubert Hondermarck	Oncogenes	2005	.
Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules Yoh Dobashi, Nobuko Takei, Shioto Suzuki, Hiroko Yoneyama, Mitsuhiko Hanawa, Akishi Ooi	Mod Pathol	2004	.
Effects of Insulin-like Growth Factor Binding Protein-3 and Farnesyltransferase Inhibitor SCH66336 on Akt Expression and Apoptosis in Non-Small-Cell Lung Cancer Cells H.-Y. Lee, H. Moon, K.-H. Chun, Y.-S. Chang, K. Hassan, L. Ji, R. Lotan, F. R. Khuri, W. K. Hong	J Natn Cancer Inst	2004	.
Tyrosine kinases as targets in cancer therapy – successes and failures Peter Traxler	eott	2003	.
The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 (‘Iressa’11Iressa’ is a trademark of the AstraZeneca group of companies.) is not related to the expression of EGFR or HER-2 or to K-ras gene status Takeshi Suzuki, Taku Nakagawa, Hideki Endo, Tetsuya Mitsudomi, Akira Masuda, Yasushi Yatabe, Takahiko Sugiura, Takashi Takahashi, Toyoaki Hida	Lung Cancer	2003	.
Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo Heather B. Adkins, Caterina Bianco, Susan G. Schiffer, Paul Rayhorn, Mohammad Zafari, Anne E. Cheung, Olivia Orozco, Dian Olson, Antonella De Luca, Ling Ling Chen, Konrad Miatkowski, Chris Benjamin, Nicola Normanno, Kevin P. Williams, Matthew Jarpe, Doreen LePage, David Salomon, Michele Sanicola	Journal Clinical Investigation	2003	.

« Previous 1 2 Next »